TICKERNERD
Menu
CDTCDTHealthcare · Biotechnology

CDT Stock Forecast: CDT Equity, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.17

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap
$2.4M
Ticker Nerd rank
11 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$3.0M
Net income−$4.6M
Free cash flow−$544K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CDT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CDT Equity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
43
Growth
39
Quality
33
Issuance
30
Revisions
25
Value
6
Volatility
6
Momentum
1

Size (99): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDT, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CDT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

CDT Equity, Inc. (CDT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
421.3×

Cheaper than 2% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−69.7%

Higher than 17% of US stocks

Return on assets
−23.4%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CDT Equity, Inc. (CDT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CDT Equity, Inc. has a market value of $2.4M and an enterprise value of $572K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.5M.

  • Shares outstanding: 472,245.

  • Trailing P/E: 421.3×.

  • CDT Equity, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

CDT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CDTCDT Equity, Inc.$2.4M
11
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44
SLXNSilexion Therapeutics Corp.$2.4M
53
SPRCSciSparc Ltd.$2.6M
19
ARTLArtelo Biosciences, Inc.$2.2M
15
PPCBPropanc Biopharma, Inc.$2.1M
40
CMNDClearmind Medicine, Inc.$2.7M
6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CDT Equity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDT news & analysis

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

GlobeNewsWire · 18 Sept 2026positive

CDT has entered a partnership with QIMA Life Sciences to evaluate novel tapinarof combinations for the treatment of psoriasis and vitiligo. The collaboration will assess combination approaches involving CDT's tapinarof product.

Why it matters — This partnership signals CDT's continued investment in expanding its tapinarof pipeline into new combination therapies for dermatological conditions.

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

GlobeNewsWire · 10 Sept 2026neutral

CDT highlighted Sarborg's application of its Signature Intelligence and quantum computing models to the field of mental health, as announced from Naples, Florida and Cambridge, United Kingdom. The announcement focuses on the technological application of these models in this domain.

Why it matters — A CDT watcher would care because it showcases how CDT's Signature Intelligence and quantum computing capabilities are being applied to a new and significant sector, potentially expanding the practical uses of its technology.

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

GlobeNewsWire · 2 Sept 2026positive

CDT Equity, Inc. issued a capital update confirming it has no Nasdaq deficiencies. The announcement was released from the company's Naples, Florida and Cambridge, United Kingdom offices.

Why it matters — CDT watchers would care because confirmation of no Nasdaq listing deficiencies signals the company remains compliant with exchange requirements.

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

GlobeNewsWire · 1 Sept 2026positive

CDT Equity, Inc. announced it has appointed co-founder James Bligh as Chief Executive Officer to lead the company's next phase of growth. The announcement was made from the company's offices in Naples, Florida and Cambridge, United Kingdom.

Why it matters — A co-founder taking the CEO role signals continuity of leadership and strategic direction as CDT enters its next growth phase.

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

GlobeNewsWire · 28 Aug 2026positive

CDT Equity Inc. announced that new solid forms and alternative crystal structures of its existing drug compounds demonstrate improved physical properties, including enhanced stability, solubility, and manufacturability compared to existing forms of these compounds.

Why it matters — This development could strengthen the value of CDT's existing intellectual property portfolio by potentially improving the performance and production of its drug compounds.

FAQ

Frequently asked questions about CDT stock

How does Ticker Nerd's model rank CDT?

As at 19 Sept 2026, CDT Equity, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the CDT stock forecast for 2030?

No analyst covering CDT Equity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDT are extrapolating price history, which says nothing about the business.

What does CDT Equity, Inc. do?

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships.

What is the latest news on CDT?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo". CDT has entered a partnership with QIMA Life Sciences to evaluate novel tapinarof combinations for the treatment of psoriasis and vitiligo. The collaboration will assess combination approaches involving CDT's tapinarof product.

Company

About CDT Equity, Inc.

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships. CDT Equity Inc. develops clinical-stage programs across autoimmune diseases, oncology, dermatology, idiopathic male infertility, rare diseases, and animal health. Its current portfolio includes compounds such as AZD1656, AZD5658, and AZD5904, supported by an approach that combines artificial intelligence, solid-form chemistry, and asset repositioning to improve development efficiency. The company emphasizes value creation through intellectual property, out-licensing, and partnerships rather than large-scale internal drug development. CDT Equity Inc. serves as a specialized participant in the healthcare sector, aiming to bring differentiated treatment candidates into clinical and commercial pathways.

CEO Dr. David Joszef Tapolczay · 4 employees · United States · https://www.cdtequity.com